Type 2 Inflammation

 

California State Senator Melissa Hurtado

Carole Huntsman, Head, Sanofi Genzyme North America and US Country Lead

Dr. Mandeep Kaur, Vice President, Head, North America Medical for Dupixent at Sanofi Genzyme

Dr. Tyra Bryant-Stephens, Director and Founder, The Community Asthma Prevention Program, Clinical Professor of Pediatrics, The Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania

 

People of all ages, genders, and backgrounds are connected by similar challenges because of one lesser known chronic condition known as Type 2 Inflammation. Recent scientific developments have shown that this overactive immune system response, underlies different atopic, allergic and inflammatory diseases. What exactly does that mean and how does it affect our families and communities? On this episode of the Women In Government Podcast, our panel discusses how the Type 2 Inflammation connection can help patients work with their doctors to gain control of their chronic disease.

 

As for policymakers and industry leaders, these chronic conditions impact communities of color and those in underserved communities. Now’s the time to get to work and support measures to address Type 2 Inflammation.